OakChart

NanoViricides Inc

NNVCHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 11:53 AM ET

1.420.00 (0.00%)
2026-11-11 17:54 CET
Market cap
36.25 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-8.22 USD m
Free cash flow, TTM
-7.78 USD m
EPS diluted, TTM
-0.41
P/E
-
Compare

Price

NNVC against its 20, 50 and 200-day averages
2050200beatearnings
1.001.251.501.7514.5M28.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NNVCclose 1.4220-day 1.3950-day 1.33200-day 1.301.4252w high

26.4% under the 52-week high of 1.93 on 28 May 2026. 52-week low 0.85 on 5 Feb 2026. Last 15 sessions, 21.4% high to low

Profile

NNVC
52-week range, 53% of the way up
0.851.93

NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. It focuses on anti-viral therapeutics through internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Employees7
IPOAug 12, 2004
Beta1.81
ATR, 14d0.10
Rel volume0.62
Short float3.26%
Insider own2.49%
Inst own9.40%

Snapshot

6 groups

Valuation

Index-
Market Cap36.25M
Enterprise Value33.46M
Income-8.22M
Sales0.00M
Book/sh0.38
Cash/sh0.11
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees7
IPOAug 12, 2004

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.76
P/C12.99
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.66
Current Ratio2.66
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / No

Earnings

EPS (ttm)-0.41
EPS next Y-
EPS next Q-0.10
EPS this Y-6.98%
EPS next Y-
EPS next 5Y-
EPS past 3/5Y18.01% 12.84%
Sales past 3/5Y- -
EPS Y/Y TTM35.47%
Sales Y/Y TTM-
EPS Q/Q21.51%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.-10.00% -

Ownership

Insider Own2.49%
Insider Trans0.00%
Inst Own9.40%
Inst Trans1.64%
ROA-87.91%
ROE-101.46%
ROIC-94.65%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA202.16%
SMA506.64%
SMA2009.32%
Trades-

Technical

Shs Outstand25.52M
Shs Float24.89M
Short Float3.26%
Short Ratio2.20
Short Interest0.81M
52W High1.93 -26.42%
52W Low0.85 67.06%
Volatility7.56% 7.43%
ATR (14)0.10
RSI (14)53.40
Beta1.81
Rel Volume0.62
Avg Volume368.37K
Volume91,032

Performance

Perf Week2.90%
Perf Month7.58%
Perf Quarter4.41%
Perf Half Y-17.44%
Perf YTD25.66%
Perf Year-10.69%
Perf 3Y33.96%
Perf 5Y-69.26%
Perf 10Y-94.86%
Recom1.00
Target Price6.00
Prev Close1.42
Price1.42
Change %0.00%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Dec 16, 2025InitiatedAAlliance Global PartnersBuy
Feb 11, 2015InitiatedMMidtown PartnersStrong Buy$5.30+273.2%

Peers

Mkt cap
TickerCompanyMkt cap
COCPCocrystal Pharma Inc19.83M
ALGSAligos Therapeutics Inc16.49M
ENTAEnanta Pharmaceuticals Inc333.63M
TRAWTraws Pharma Inc3.73M
AVIRAtea Pharmaceuticals Inc336.48M
IVVDInvivyd Inc174.53M
SIGASIGA Technologies Inc231.02M
VIRVir Biotechnology Inc2.25B
TNXPTonix Pharmaceuticals Holding Corp77.63M
EBSEmergent Biosolutions Inc312.60M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 206
  • As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides (ACCESSWIRE) +7.35%
  • NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials (ACCESSWIRE) +13.85%
  • Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides (ACCESSWIRE)
  • NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 (ACCESSWIRE)
  • NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives (ACCESSWIRE) +13.28%
  • Loading…
  • NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials (ACCESSWIRE) -13.33%
  • NanoViricides: Fiscal Q4 Earnings Snapshot (Associated Press)
  • Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides (ACCESSWIRE)
  • Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides (ACCESSWIRE)
  • Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in ?DR Congo with 48% Crude Fatality Rate, Says NanoViricides (ACCESSWIRE)
  • Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo (ACCESSWIRE)
  • While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles (ACCESSWIRE)
  • The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-09-02-0.110-0.100-0.1000.000.002
2026Q32026-05-19-0.095--0.0920.00--
2026Q22026-02-11-0.110-0.110-0.1120.000.002
2026Q12025-12-03-0.135-0.180-0.1050.000.001
2025Q42025-09-03-0.120--0.1270.00--
2024Q32024-05-14-0.510-0.150-0.1570.00-1
2024Q22024-02-16-0.180-0.190-0.1800.00-1
2023Q22023-05-13-0.150--0.150--1
2023Q12023-01-28-0.140--0.136--1
2022Q42022-10-14-0.150--0.154--1
2022Q32022-05-17-0.160-0.160-0.155--1
2022Q22022-04-13-0.170--0.167---
2024Q4---0.310-0.193--1
2025Q1---0.170-0.228--1
2025Q2---0.180-0.139--1
2025Q3---0.190-0.138--1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2011FY-3.500-3.500-3.500-0.00
2014FY-5.600-4.600-5.600-0.00
2020FY-2.390--2.3940.00-
2022FY-0.700--0.703--
2023FY-0.430-0.430-0.739--
2025FY-0.630--0.6260.00-
2026FY-0.430-0.415-0.4300.000.00
2027FY--0.460--0.00
2028FY-0.500--76.50
2029FY-0.950--133.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2026-09-021000.000.000.00
2027Q1S2026-07-021000.000.000.00
2027Q1R2026-09-02100-0.10-0.10-0.10
2027Q1R2026-07-02100-0.10-0.10-0.10
2027Q1E2026-09-02100-0.10-0.10-0.10
2027Q1E2026-07-07200-0.10-0.10-0.09
2027Q1E2026-07-02210-0.10-0.10-0.09
2027Q1E2026-05-19110-0.09-0.09-0.09
2027Q1E2026-02-11100-0.10-0.10-0.10
2027Q1E2025-12-12100-0.10-0.10-0.10
2027FYS2026-09-021000.000.000.00
2027FYS2025-11-111000.000.000.00
2027FYS2025-11-101000.000.000.00
2027FYS2025-11-091000.000.000.00

Estimate history

EPS, annual-2.6-2.347-2.394-0.809-0.703-0.739-0.699-0.626-0.407
Period201820192020202120222023202420252026
EPS, quarterly-0.193-0.228-0.139-0.138-0.127-0.105-0.112-0.092-0.1
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual000000000
Period201820192020202120222023202420252026
Sales, quarterly000000000
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual3.4593.8459.08311.51511.59211.69813.14416.60723.008
Period201820192020202120222023202420252026
Shares, quarterly13.14414.06315.64216.07216.60717.55621.59521.64723.008
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.530.530.740.760.750.720.700.700.70
Gross Profit-0.53-0.53-0.74-0.76-0.75-0.72-0.70-0.70-0.70
Selling, General and Administrative Excl. Other7.787.788.857.768.207.398.047.307.96
Research and Development4.714.715.555.446.395.786.114.705.92
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-8.31-8.31-9.59-8.52-8.94-8.11-8.74-8.00-8.66
Interest Expense0.000.000.000.050.000.010.090.090.00
Unusual Expense0.000.000.000.000.000.000.005.99-0.18
Net Income Before Taxes-8.22-8.22-9.47-8.29-8.59-8.11-8.82-13.45-8.42
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-8.22-8.22-9.47-8.29-8.59-8.11-8.82-13.45-8.42
Net Income From Continuing Operations-8.22-8.22-9.47-8.29-8.59-8.11-8.82-13.45-8.42
Net Income-8.22-8.22-9.47-8.29-8.59-8.11-8.82-13.45-8.42
EPS (Recurring)-0.37-0.41-0.63-0.70-0.74-0.70-0.81-1.65-2.38
EPS (Basic, Before Extraordinaries)-0.41-0.41-0.63-0.70-0.74-0.70-0.81-2.39-2.35
EPS (Diluted)-0.41-0.41-0.63-0.70-0.74-0.70-0.81-2.39-2.35
EBITDA-7.78-7.78-8.85-7.76-8.20-7.39-8.04-7.30-7.96
Non-Operating Income (Expense)0.090.090.120.270.360.010.010.630.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.050.050.060.050.060.140.240.260.01
Shares Outstanding23.0123.0116.6113.1411.7011.5911.529.083.84
Market Capitalization36.2536.2522.5020.3213.4221.7253.3867.8718.42

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.130.130.130.130.160.190.200.20
Gross Profit-0.13-0.13-0.13-0.13-0.16-0.19-0.20-0.20
Selling, General and Administrative Excl. Other2.121.902.101.661.952.061.862.97
Research and Development1.311.291.120.991.181.281.161.93
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.25-2.03-2.23-1.80-2.12-2.25-2.06-3.17
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.22-1.99-2.22-1.79-2.10-2.22-2.03-3.13
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.22-1.99-2.22-1.79-2.10-2.22-2.03-3.13
Net Income From Continuing Operations-2.22-1.99-2.22-1.79-2.10-2.22-2.03-3.13
Net Income-2.22-1.99-2.22-1.79-2.10-2.22-2.03-3.13
EPS (Recurring)-0.10-0.09-0.11-0.10-0.13-0.14-0.14-0.23
EPS (Basic, Before Extraordinaries)-0.10-0.09-0.11-0.10-0.13-0.14-0.14-0.23
EPS (Diluted)-0.10-0.09-0.11-0.10-0.13-0.14-0.14-0.23
EBITDA-2.12-1.90-2.10-1.66-1.95-2.06-1.86-2.97
Non-Operating Income (Expense)0.020.040.010.010.020.030.030.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.010.010.010.010.020.060.010.01
Shares Outstanding23.0121.6521.6017.5616.6116.0715.6414.06
Market Capitalization36.2519.7024.3722.9822.5018.3020.5217.72

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments2.791.564.808.1514.0720.5213.712.567.08
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.370.110.170.300.350.310.280.270.24
Total Current Assets3.161.674.978.4514.4220.8213.992.837.32
Net Property, Plant & Equipment6.406.837.518.118.699.089.5410.2310.84
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.310.320.330.330.340.350.360.370.37
Other Assets0.000.000.010.010.040.000.030.030.01
Total Assets9.878.8212.8216.9023.4930.2623.9113.4518.55
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.090.101.140.000.00
Accounts Payable1.151.281.100.390.270.230.941.130.33
Other Current Liabilities0.040.030.260.140.050.020.071.710.55
Total Current Liabilities1.191.311.360.530.410.352.162.850.88
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.001.500.000.000.000.000.00
Total Liabilities1.191.311.362.030.410.352.162.850.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value9E-069E-069E-065E-060.000.000.000.010.00
Common Equity8.687.5211.4614.8723.0829.9121.7610.6017.66
Total Shareholders Equity8.687.5211.4614.8723.0829.9121.7610.6017.66
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity8.687.5211.4614.8723.0829.9121.7610.6017.66
Total Liabilities & Stockholders Equity9.878.8212.8216.9023.4930.2623.9113.4518.55
Book Value Per Share0.380.450.871.271.992.602.402.765.11
Tangible Book Value Per Share0.360.430.851.241.962.572.362.665.00
Full-Time Employees77771717171730
Price to Book Ratio3.762.551.910.910.941.793.121.451.59
Return on Assets-87.91-87.47-55.81-42.52-30.16-32.57-71.98-52.66-37.60
Return on Equity-101.46-99.75-63.00-45.27-30.60-34.15-83.11-59.61-45.09
Return on Invested Capital-94.65-125.93-72.35-57.77-35.12-29.49-61.80-79.47-48.48
Quick Ratio2.661.283.6615.8134.9259.306.490.998.30
Current Ratio2.661.283.6615.8134.9259.306.490.998.30

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-8.22-8.22-9.47-8.29-8.59-8.11-8.82-13.45-8.42
Depreciation0.530.530.740.760.750.720.700.700.70
Other Funds (Non Cash)0.370.370.220.220.371.280.445.950.36
Funds from Operations-7.33-7.33-8.50-7.31-7.47-6.11-7.67-6.80-7.37
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.37-0.370.021.001.800.21-0.540.120.57
Cash from Operating Activities-7.70-7.70-8.48-6.32-5.67-5.89-8.21-6.68-6.80
Capital Expenditures-0.08-0.08-0.06-0.16-0.15-0.32-0.24-0.01-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.08-0.08-0.06-0.16-0.15-0.32-0.24-0.01-0.07
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock9.029.025.303.120.000.0016.5616.682.35
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock9.029.025.303.120.000.0016.5616.682.35
Proceedsfrom Stock Options9.029.025.303.120.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-0.09-0.23-1.301.160.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities9.029.025.303.12-0.09-0.2315.2617.842.35
Net Change in Cash1.241.24-3.24-3.35-5.92-6.456.8111.15-4.53
Free Cash Flow-7.78-7.78-8.54-6.47-5.82-6.22-8.45-6.69-6.88
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments2.793.215.151.131.562.54
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.370.160.150.130.110.18
Total Current Assets3.163.385.301.251.672.73
Net Property, Plant & Equipment6.406.536.666.796.836.98
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.310.310.310.310.320.32
Other Assets0.000.000.000.000.000.00
Total Assets9.8710.2212.278.368.8210.03
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.151.041.151.161.281.17
Other Current Liabilities0.040.030.050.030.030.03
Total Current Liabilities1.191.071.201.181.311.20
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.191.071.201.181.311.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value9E-069E-069E-069E-069E-069E-06
Common Equity8.689.1511.077.177.528.83
Total Shareholders Equity8.689.1511.077.177.528.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.689.1511.077.177.528.83
Total Liabilities & Stockholders Equity9.8710.2212.278.368.8210.03
Book Value Per Share0.380.420.510.410.450.55
Tangible Book Value Per Share0.360.410.500.390.430.53
Full-Time Employees7---7-
Price to Book Ratio3.762.162.773.162.551.76
Return on Assets-87.91-79.91-69.79-80.86-87.47-90.50
Return on Equity-101.46-89.97-77.53-94.03-99.75-99.84
Return on Invested Capital-25.61-21.73-20.06-24.88-27.88-25.10
Quick Ratio2.663.174.431.061.282.27
Current Ratio2.663.174.431.061.282.27

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-2.22-1.99-2.22-1.79-2.10-2.22
Depreciation0.130.130.130.130.160.19
Other Funds (Non Cash)0.050.070.200.050.050.06
Funds from Operations-2.04-1.79-1.89-1.60-1.88-1.97
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.08-0.14-0.160.010.18-0.02
Cash from Operating Activities-2.12-1.93-2.05-1.59-1.70-1.99
Capital Expenditures-1E-060.001E-06-0.08-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1E-060.001E-06-0.08-0.010.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.00---0.00
Change in Capital Stock1.70-0.016.071.250.730.58
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.70-0.016.071.250.730.58
Proceedsfrom Stock Options7.110.000.661.250.730.58
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.70-0.016.071.250.730.58
Net Change in Cash-0.42-1.944.02-0.43-0.98-1.42
Free Cash Flow-2.12-1.93-2.05-1.68-1.71-1.99

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.26%0.8M24.9M390.10K
2026-10-154.59%1.1M24.9M422.45K
2026-09-303.72%0.9M24.9M447.93K
2026-09-152.36%0.6M24.9M353.79K
2026-08-312.59%0.6M24.9M353.06K
2026-08-143.52%0.9M24.8M923.99K
2026-07-312.41%0.6M24.7M946.75K
2026-07-153.27%0.7M22.4M943.95K
2026-06-303.96%0.9M22.4M895.23K
2026-06-153.37%0.8M22.4M859.98K
2026-05-297.47%1.7M22.2M850.52K
2026-05-153.34%0.7M21.1M281.06K
2026-04-303.40%0.7M21.0M249.70K
2026-04-153.49%0.7M21.0M247.96K
2026-03-313.60%0.8M21.0M266.74K
2026-03-133.84%0.8M21.0M285.67K
2026-02-274.59%1.0M21.0M297.78K
2026-02-134.02%0.8M21.0M311.34K
2026-01-303.77%0.8M21.0M346.67K
2026-01-153.14%0.7M21.0M370.27K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.052.9444880.000.170-0.0090.001
call5.000.000.250.004.8850.000.000.121-0.0120.000
call7.500.000.050.055.8941000.000.108-0.0130.000
put2.500.701.451.177.2650.000.00-0.830-0.0080.001
put5.003.004.100.0011.8380.000.00-0.879-0.0110.000
put7.505.306.800.0014.8030.000.00-0.893-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-21424B5SEC
2026-10-08DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-21SEC
2026-09-298-KCurrent report2026-09-28SEC
2026-09-2810-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-03424B3SEC
2026-08-31EFFECTEffectiveness filing by commission orderSEC
2026-08-21S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-308-KCurrent report2026-07-24SEC
2026-07-27424B5SEC
2026-07-27424B5SEC
2026-07-178-KCurrent report2026-07-17SEC
2026-07-17424B5SEC
2026-07-01424B3SEC
2026-06-26EFFECTEffectiveness filing by commission orderSEC
2026-06-23CORRESPSEC
2026-06-22DEL AMSeparately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statementSEC
2026-06-18UPLOADUpload SubmissionSEC
2026-06-17DEL AMSeparately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statementSEC
2026-06-15EFFECTEffectiveness filing by commission orderSEC
2026-06-15S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-11CORRESPSEC
2026-06-10UPLOADUpload SubmissionSEC
2026-06-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-218-KCurrent report2026-05-20SEC
2026-05-208-KCurrent report2026-05-15SEC
2026-05-18424B5SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-02-25DNotice of sales of securities on Form D (Regulation D)SEC
2026-02-1710-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2025-12-30424B3SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.00%
GEODE CAPITAL MANAGEMENT, LLC0.90%
Connective Capital Management, LLC0.81%
BlackRock, Inc.0.69%
VANGUARD FIDUCIARY TRUST CO0.57%
RENAISSANCE TECHNOLOGIES LLC0.56%
Miller Financial Services LLC0.52%
Creative Planning0.34%
UBS Group AG0.28%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.26%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.84%
VANGUARD EXTENDED MARKET INDEX FUND1.07%
Fidelity Extended Market Index Fund0.49%
Ultra-Small Company Market Fund0.16%
Fidelity Series Total Market Index Fund0.14%
Fidelity Total Market Index Fund0.09%
VANGUARD BALANCED INDEX FUND0.09%

OakChart. NNVC. Cached 15 minutes.

Some panels did not load: insider.